Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan

[1]  M. Imamura,et al.  Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure. , 2018, The Journal of general virology.

[2]  T. Masaki,et al.  Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan , 2018, Journal of Gastroenterology.

[3]  A. Tamori,et al.  The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor‐naïve patients with chronic HCV genotype 1b infection in a real‐world cohort , 2018, Journal of viral hepatitis.

[4]  J. Kao,et al.  Daclatasvir/asunaprevir/beclabuvir, all‐oral, fixed‐dose combination for patients with chronic hepatitis C virus genotype 1 , 2017, Journal of gastroenterology and hepatology.

[5]  N. Enomoto,et al.  Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection , 2017, Journal of Gastroenterology.

[6]  M. Moriguchi,et al.  Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions , 2017, World journal of hepatology.

[7]  Yoshiyuki Suzuki,et al.  The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real‐life settings , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[8]  H. Yoshiji,et al.  Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection , 2017, Journal of Gastroenterology.

[9]  H. Yoshiji,et al.  The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study , 2016, Journal of Gastroenterology.

[10]  N. Enomoto,et al.  Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure , 2016, PloS one.

[11]  H. Nomura,et al.  Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1 , 2016, Journal of Gastroenterology.

[12]  K. Chayama,et al.  HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy , 2015, Viruses.

[13]  K. Chayama,et al.  Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis , 2015, Hepatology.

[14]  T. Ide,et al.  Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. , 2015, The Lancet. Infectious diseases.

[15]  G. Dore,et al.  Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. , 2015, JAMA.

[16]  T. Hassanein,et al.  A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. , 2015, Journal of hepatology.

[17]  S. Mochida,et al.  A Novel Simple Assay System to Quantify the Percent HCV-RNA Levels of NS5A Y93H Mutant Strains and Y93 Wild-Type Strains Relative to the Total HCV-RNA Levels to Determine the Indication for Antiviral Therapy with NS5A Inhibitors , 2014, PloS one.

[18]  K. Chayama,et al.  Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection , 2014, Hepatology.

[19]  P. Marcellin,et al.  Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. , 2014, Gastroenterology.

[20]  S. Pol,et al.  FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest , 2007, Hepatology.

[21]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[22]  M. Mizokami,et al.  New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a , 1997, Journal of clinical microbiology.

[23]  P. Bedossa,et al.  Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C , 1994 .